$64.60 If paid in BTC $51.68
•USA: $6.95 (3-7 business days)
•CA: $10.50 (3-7 business days)
•International: $39 (7-14 business days)
If your shipment was seized (International Orders), we will provide a 50% discount applicable on your next purchase. Please contact us for more information.ASD
Quantity: 100 tabs
Packaging: Capsulated and in Mylar Bags
Label: 7.5cm x 2.8cm
Product made and housed in the USA and Europe.
Raloxifene was developed in 1997 and sold under the brand name Evista among others, is a medication that is used in postmenopausal women and to reduce the risk of breast cancer in postmenopausal women with osteoporosis or at high risk for breast cancer. Raloxifene was first presented, for the avoidance of postmenopausal osteoporosis, in 1997. It was subsequently approved for the treatment of postmenopausal osteoporosis in 1999 and to reduce the risk of breast cancer in certain women in 2007
Raloxifene is shown for the treatment and anticipation of osteoporosis in postmenopausal ladies. It is also used for the reduction of risk and treatment of invasive breast cancer, and it also reduces breast density. Raloxifene has been found as viable in the treatment in the treatment of gynecomastia (male breast development) in adolescents. For either osteoporosis treatment or prevention, supplemental calcium and/or vitamin D ought to be added to the eating routine if day by day admission is insufficient.
Raloxifene is contraindicated in lactating women or women who are or may get pregnant.
It also may be of concern to women with an active or past history of venous thromboembolic events, including deep vein thrombosis, pulmonary embolism, and retinal vein thrombosis.
All of our products are laboratory tested and the results are periodically published on the website.
Also known as: Keoxifene; Pharoxifene; LY-139481; LY-156758; CCRIS-7129